Palbociclib is a member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combination with letrozole for the treatment of metastatic breast cancer. It is grouped under the following drug class(es): Antineoplastic agents, CDK4/6 Inhibitors and Kinase inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ibrance and palbociclibum. Its PubChem CID is 5330286.
Palbociclib
| CAS No | 571190-30-2 |
|---|---|
| Molecular Formula | C24H29N7O2 |
| Molecular Weight | 447.5 g/mol |
| Synonyms | 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Palbociclib is a member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively.
The listed CAS number is 571190-30-2.
The listed molecular formula is C24H29N7O2.
The listed molecular weight is 447.5 g/mol.
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one.
The source lists Ibrance and palbociclibum.